Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)
dc.contributor.author | Segarra Echevarria, Rafael | |
dc.contributor.author | Recio Barbero, María | |
dc.contributor.author | Sáenz Herrero, Margarita | |
dc.contributor.author | Mentxaka Solozabal, Oihane | |
dc.contributor.author | Cabezas Garduño, Janire | |
dc.contributor.author | Eguiluz Urruchurtu, José Ignacio | |
dc.contributor.author | Callado Hernando, Luis Felipe ![]() | |
dc.date.accessioned | 2021-12-22T11:55:37Z | |
dc.date.available | 2021-12-22T11:55:37Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | International Journal of Neuropsychopharmacology 24(9) : 694-702 (2021) | es_ES |
dc.identifier.issn | 1461-1457 | |
dc.identifier.issn | 1469-5111 | |
dc.identifier.uri | http://hdl.handle.net/10810/54620 | |
dc.description.abstract | Background: Long-acting injectable antipsychotics (LAIs) may be a suitable therapeutic option for those patients in earlier stages of psychosis to avoid relapses and disease progression. Despite that, there is a lack of evidence in the literature regarding the use of LAIs in this profile of patients. Methods: This is a retrospective cohort analysis to assess the efficacy, tolerability, and pattern of use of palmitate paliperidone long-acting injectable (PPLAI) formulations (1- and 3-month doses) compared to oral paliperidone/risperidone in patients with a nonaffective first episode of psychosis (FEP) over 12 months of follow-up. Relevant sociodemographic and clinical information were assessed, as well as main clinical scales: Positive and Negative Syndrome Scale, Personal and Social Performance Scale, and Clinical Global Impression Scale Improvement and Severity measures. Results: The study included 48 patients, 16 per arm, who were aged 20-50 years and had an FEP. Significant improvements were registered for all treatment groups. Despite that, patients receiving PPLAI 1- and 3-month formulations obtained greater improvements than those in the oral group in the main domains assessed (P < .001). We found no statistically significant differences in hospitalizations between groups. Side effects were presented in 24% of patients. A trend towards reducing antipsychotic doses was observed in 43.8% of patients to achieve the minimum effective dose and avoid the occurrence of side effects. Conclusions: To our knowledge, this is the first study assessing the use of palmitate paliperidone long-acting formulations versus oral risperidone or paliperidone in FEP. Treatment with PPLAI formulations seems to be an effective therapeutic choice at earlier stages of the disease. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | first episode psychosis | es_ES |
dc.subject | long-acting injectable antipsychotics | es_ES |
dc.subject | paliperidone | es_ES |
dc.subject | recent-onset psychosis | es_ES |
dc.subject | risperidone | es_ES |
dc.subject | schizophrenia spectrum disorders | es_ES |
dc.subject | nonaffective psychosis | es_ES |
dc.subject | functional recovery | es_ES |
dc.subject | recent-onset | es_ES |
dc.subject | relapse | es_ES |
dc.subject | predictors | es_ES |
dc.subject | discontinuation | es_ES |
dc.subject | antipsychotics | es_ES |
dc.subject | metaanalysis | es_ES |
dc.subject | remission | es_ES |
dc.title | Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP) | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | The Author(s) 2021. Published by Oxford University Press on behalf of CINP. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://academic.oup.com/ijnp/article/24/9/694/6261963 | es_ES |
dc.identifier.doi | 10.1093/ijnp/pyab021 | |
dc.departamentoes | Farmacología | es_ES |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Farmakologia | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as The Author(s) 2021. Published by Oxford University Press on behalf of CINP.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and
reproduction in any medium, provided the original work is properly cited